Hepatitis C is the only form of viral hepatitis that can be completely cured with current medicine. A simple oral treatment lasting 8 to 12 weeks eliminates the virus in more than 95% of people, regardless of the strain they carry or how long they’ve been infected. Hepatitis A resolves on its own without treatment in nearly all cases, while hepatitis B and D can be managed but not yet cured.
Hepatitis C: A Complete Cure
Hepatitis C went from being a lifelong, liver-damaging infection to a curable disease in less than a decade. The breakthrough came with a class of medications called direct-acting antivirals, which became widely available starting around 2014. These pills work by targeting specific proteins the virus needs to copy itself, and they succeed in more than 95% of patients. That cure rate holds across all six major strains of the virus and applies equally to people with HIV, those with significant liver scarring, and patients of all racial backgrounds.
Treatment typically lasts 8 to 12 weeks, taken as one or two pills per day. Side effects are mild compared to older treatments, which involved injections and caused flu-like symptoms for months. Once you finish the course, your doctor confirms the cure with a blood test 12 weeks later. If no viral genetic material is detectable at that point, you’re considered cured. This milestone is called a sustained virologic response, and late relapses after reaching it are extremely rare.
The tests used to confirm a cure are sensitive enough to detect as few as 5 to 12 international units of virus per milliliter of blood, depending on the lab. Rapid point-of-care tests can also be used, with slightly higher detection thresholds. If nothing shows up, the virus is gone.
Why Curing Hepatitis C Can Still Be Difficult
The medical side is straightforward. The practical side is not. The wholesale cost of a full treatment course has historically ranged from roughly $84,000 to over $150,000, depending on the specific drug combination. While prices have dropped with the introduction of generic versions, access remains uneven.
In the United States, most insurance plans cover these medications but layer on barriers. Nearly all Medicare Part D plans require prior authorization, and most place the drugs on specialty tiers with coinsurance rather than a flat copay. For people without low-income subsidies, out-of-pocket costs for a full course of treatment have averaged between $6,300 and $10,900. Those who qualify for subsidies pay dramatically less, sometimes under $11 total. The gap between those two realities reflects how insurance structure, not medical science, often determines who gets cured.
Globally, the World Health Organization has set a target of reducing new hepatitis infections by 90% and hepatitis-related deaths by 65% compared to 2015 levels, all by 2030. Affordable generic versions of the cure exist in many lower-income countries, but screening remains a bottleneck: millions of people with hepatitis C don’t know they have it.
Hepatitis A: Clears on Its Own
Hepatitis A doesn’t become chronic. Your immune system fights it off within weeks to a few months, and once it’s gone, you’re immune for life. There’s no specific antiviral treatment because none is needed. Most people recover fully with rest and symptom management, though the illness itself can be miserable, with fatigue, nausea, and jaundice lasting several weeks. A safe, effective vaccine prevents it entirely.
Hepatitis B: Managed but Not Yet Cured
Chronic hepatitis B affects an estimated 250 million people worldwide, and it cannot be cured with current treatments. The virus inserts its genetic material into the nuclei of liver cells in a form that’s extremely difficult to eliminate. Antiviral medications can suppress the virus to very low or undetectable levels, protecting the liver from ongoing damage, but most people need to stay on treatment indefinitely. Stopping medication often leads to the virus rebounding.
A small percentage of people do achieve what’s called a “functional cure,” where a key viral protein disappears from the blood and the immune system gains lasting control. This happens spontaneously in some patients and occasionally during treatment, but it’s the exception. Doctors decide when to start antiviral therapy based on how much liver inflammation and scarring is present and how actively the virus is replicating.
The research pipeline for a true hepatitis B cure is extensive. Dozens of experimental approaches are in clinical trials, including drugs that silence viral genes, compounds that stop the virus from entering liver cells, therapeutic vaccines designed to retrain the immune system, and even gene-editing tools that aim to cut viral DNA out of infected cells. Several of these are in mid-to-late-stage trials. While no cure is imminent, the breadth of the effort is unlike anything seen before for this virus.
Prevention remains the most effective tool. The hepatitis B vaccine, given at birth in most countries, provides long-lasting protection and has already dramatically reduced new infections in younger generations.
Hepatitis D: The Hardest to Treat
Hepatitis D only infects people who already have hepatitis B, because it depends on hepatitis B’s surface protein to survive. It’s the most severe form of viral hepatitis, accelerating liver damage far beyond what hepatitis B causes alone. A cure remains elusive.
The only widely available treatment is a year or longer course of injectable interferon, a drug that stimulates the immune system but is poorly tolerated and modestly effective. In the largest studies, only 21% to 24% of patients had undetectable virus after a year of treatment, and many of those relapsed afterward. Extending treatment to two years improved response rates to around 40%, but relapse remained common. One long-term follow-up study found that 58% of patients treated with extended courses eventually maintained an undetectable viral load, though these were carefully selected patients in a prospective study, not typical outcomes.
Because hepatitis D requires hepatitis B to exist, preventing hepatitis B through vaccination also prevents hepatitis D entirely. For the roughly 12 to 72 million people already living with both viruses, effective treatment options remain limited, though new entry-blocking drugs are in advanced clinical trials.
How the Types Compare at a Glance
- Hepatitis A: No chronic form. Resolves on its own. Vaccine available.
- Hepatitis B: Chronic infection manageable with long-term medication but not curable. Vaccine available.
- Hepatitis C: Curable in over 95% of cases with 8 to 12 weeks of oral medication. No vaccine available.
- Hepatitis D: Not curable. Limited treatment options with low success rates. Prevented by hepatitis B vaccination.